Disease‐Associated Risk Variants and Expression Levels of the lncRNA , CDKN2B ‐ AS1 , Are Associated With the Progression of HCC
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70496 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Kuan-Chun Hsueh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Surgery, Department of Surgery, Tungs' Taichung Metroharbor Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Carcinoma, Hepatocellular, Liver Neoplasms, Polymorphism, Single Nucleotide. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The most susceptible loci of hepatocellular carcinoma (HCC) identified by genome‐wide association studies are located in non‐coding regions. The antisense non‐coding RNA at the INK4 locus (ANRIL), also known as cyclin‐dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B‐AS1), is a long non‐coding (lnc)RNA situated within and antisense to genes encoding CDKN2A/B on chromosome 9p21.3. Single‐nucleotide polymorphisms (SNPs) within CDKN2B‐AS1 are associated with several cancer types, but their impacts on HCC remain unclear. In this study, we investigated the effects of CDKN2B‐AS1 SNPs on both the susceptibility to HCC and its clinicopathological development. Five CDKN2B‐AS1 SNP loci—rs564398 (T/C), rs1333048 (A/C), rs1537373 (G/T), rs2151280 (A/G) and rs8181047 (G/A)—were analysed using a TaqMan allelic discrimination assay for genotyping in a cohort of 810 HCC patients and 1190 healthy controls. Under the dominant model, HCC patients with at least one minor C‐allele of rs564398 showed a lower risk of liver cirrhosis (odds ratio (OR) = 0.677). Additionally, HCC patients with the GT + TT genotype of rs1537373 had a reduced risk of developing large tumours (T3 + T4) and advanced clinical stages (III/IV), particularly in the male population (OR = 0.644 and 0.679). Furthermore, data from The Cancer Genome Atlas revealed that CDKN2B‐AS1 expression levels were elevated in HCC tissues compared to normal tissues and were correlated with advanced T stages, high histological grades and poor prognoses. Our findings suggest that CDKN2B‐AS1 levels and its polymorphic variants at rs564398 and rs1537373 may influence the clinicopathological development and progression of HCC in a Taiwanese population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of General Surgery, Department of Surgery, Tungs' Taichung Metroharbor Hospital, Taichung, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan.
- Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- Department of Mathematics and Statistics, Florida Atlantic University, Boca Raton, Florida, USA.
ORCID-Profile: Shun-Fa Yang, Ming-Hsien Chien
Zitieren
APA
Hsueh, K. C., Lee, H. L., Ho, K. H., Chang, L. C., Yang, S. F., & Chien, M. H. (2025). Disease‐Associated Risk Variants and Expression Levels of the lncRNA , CDKN2B ‐ AS1 , Are Associated With the Progression of HCC. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70496
Vancouver
Hsueh KC, Lee HL, Ho KH, Chang LC, Yang SF, Chien MH. Disease‐Associated Risk Variants and Expression Levels of the lncRNA , CDKN2B ‐ AS1 , Are Associated With the Progression of HCC. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70496
BibTeX
@article{Hsueh2025,
author = {Hsueh, Kuan-Chun and Lee, Hsiang-Lin and Ho, Kuo-Hao and Chang, Lun-Ching and Yang, Shun-Fa and Chien, Ming-Hsien},
title = {Disease‐Associated Risk Variants and Expression Levels of the lncRNA , CDKN2B ‐ AS1 , Are Associated With the Progression of HCC},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70496}
}
EUVIMED